A detailed history of Eagle Health Investments LP transactions in Argenx Se stock. As of the latest transaction made, Eagle Health Investments LP holds 74,990 shares of ARGX stock, worth $42.3 Million. This represents 7.71% of its overall portfolio holdings.

Number of Shares
74,990
Previous 88,890 15.64%
Holding current value
$42.3 Million
Previous $38.2 Million 6.39%
% of portfolio
7.71%
Previous 6.71%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$434.22 - $551.9 $6.04 Million - $7.67 Million
-13,900 Reduced 15.64%
74,990 $40.7 Million
Q2 2024

Aug 13, 2024

BUY
$356.01 - $451.55 $1.53 Million - $1.94 Million
4,300 Added 5.08%
88,890 $38.2 Million
Q4 2023

Feb 12, 2024

BUY
$338.91 - $506.01 $6.84 Million - $10.2 Million
20,190 Added 31.35%
84,590 $32.2 Million
Q1 2023

May 12, 2023

BUY
$334.23 - $403.65 $1.37 Million - $1.65 Million
4,100 Added 6.8%
64,400 $24 Million
Q2 2022

Aug 11, 2022

SELL
$269.58 - $378.88 $2.59 Million - $3.64 Million
-9,600 Reduced 13.73%
60,300 $22.8 Million
Q1 2022

May 12, 2022

BUY
$254.45 - $351.06 $1.93 Million - $2.66 Million
7,568 Added 12.14%
69,900 $22 Million
Q4 2021

Feb 10, 2022

BUY
$272.01 - $353.03 $2.37 Million - $3.07 Million
8,700 Added 16.22%
62,332 $21.8 Million
Q3 2021

Oct 20, 2021

BUY
$295.0 - $350.58 $118,000 - $140,232
400 Added 0.75%
53,632 $16.2 Million
Q2 2021

Jul 19, 2021

BUY
$257.11 - $319.92 $2.73 Million - $3.39 Million
10,600 Added 24.86%
53,232 $16 Million
Q1 2021

Apr 23, 2021

BUY
$268.3 - $380.31 $6.18 Million - $8.76 Million
23,045 Added 117.65%
42,632 $11.7 Million
Q4 2020

Feb 04, 2021

BUY
$248.13 - $308.36 $4.86 Million - $6.04 Million
19,587 New
19,587 $5.76 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Eagle Health Investments LP Portfolio

Follow Eagle Health Investments LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Health Investments LP, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Health Investments LP with notifications on news.